In December, we added 76 citations in DIDB, including 32 in vitro (with 22 articles published in December 2023) and 44 in vivo articles (with 36 articles published in December 2023).
5 NDA/BLAs approved in 2023, including fruquintinib (FRUZAQLA), gepirone (EXXUA), repotrectinib (AUGTYRO), toripalimab (LOQTORZI), vamorolone (AGAMREE), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.